4: Lauschke J, Schneider J, Schneider R, Nesselmann C, Tischer T, Glass A,
Bänsch D. Electrophysiological studies in patients with paroxysmal
supraventricular tachycardias but no electrocardiogram documentation: findings
from a prospective registry. Europace. 2015 May;17(5):801-6.
5: Tischer TS, Schneider R, Lauschke J, Nesselmann C, Steinhoff G, Bänsch D.
Adjunctive surgical atrial fibrillation ablation during cardiac surgery: real
life experiences. Herzschrittmacherther Elektrophysiol. 2015 Sep;26(3):291-6.
6: Schneider R, Lauschke J, Schneider C, Tischer T, Glass A, Bänsch D. Reduction
of radiation exposure during ablation of atrial fibrillation. Herz. 2015
Sep;40(6):883-91.
7: Tischer TS, Schneider R, Lauschke J, Diedrich D, Kundt G, Bänsch D.
Prevalence of atrial fibrillation and the HATCH score: Intensified monitoring of
patients with high HATCH score. Herz. 2015 Aug;40(5):803-8.
8: Lauschke J, Schneider R, Bänsch D. Supraventricular tachycardia with cycle
length variation and apparent VA dissociation: what is the mechanism? Europace.
2015 Jul;17(7):1037.
9: Schneider R, Lauschke J, Tischer T, Schneider C, Voss W, Moehlenkamp F,
Glass A, Diedrich D, Bänsch D. Pulmonary vein triggers play an important role in
the initiation of atrial flutter: Initial results from the prospective
randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial.
Heart Rhythm. 2015 May;12(5):865-71.
10: Lauschke J, Schneider R, Bänsch D. Mapping and ablation of a left atrial
macro reentrant tachycardia originating from the left superior pulmonary vein.
Herz. 2015 Apr;40 Suppl 2:137-9.
11: Tischer TS, Hollstein A, Voss W, Wendig I, Lauschke J, Schneider R, von
Knorre GH, Bänsch D. A historical perspective of pacemaker infections: 40-years
single-centre experience. Europace. 2014 Feb;16(2):235-40.
12: Lauschke J, Schneider R, Bänsch D. Ventricular tachycardia ablation in a
patient with a parachute device: a decent word of warning. Europace. 2014
Feb;16(2):207.
13: Schmidt EU, Schneider R, Lauschke J, Wendig I, Bänsch D. The HATCH and
CHA2DS 2-VASc scores. Prognostic value in pulmonary vein isolation. Herz. 2014
May;39(3):343-8.
14: Tischer Ts, Schneider R, Lauschke J, Nesselmann C, Klemm A, Diedrich D,
Kundt G, Bänsch D. Prevalence of atrial fibrillation in patients with high
CHADS2- and CHA2DS2VASc-scores: anticoagulate or monitor high-risk patients?
Pacing Clin Electrophysiol. 2014 Dec;37(12):1651-7.
15: Lauschke J, Maisch B. Athlete's heart or hypertrophic cardiomyopathy? Clin
Res Cardiol. 2009 Feb;98(2):80-8.
16: Meyer T, Lauschke J, Ruppert V, Richter A, Pankuweit S, Maisch B. Isolated
cardiac sarcoidosis associated with the expression of a splice variant coding
for a truncated BTNL2 protein. Cardiology. 2008;109(2):117-21.
17: Wetzel U, Boldt A, Lauschke J, Weigl J, Schirdewahn P, Dorszewski A, Doll N,
Hindricks G, Dhein S, Kottkamp H. Expression of connexins 40 and 43 in human
left atrium in atrial fibrillation of different aetiologies. Heart. 2005
Feb;91(2):166-70.
18: Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H,
Dhein S. Fibrosis in left atrial tissue of patients with atrial fibrillation
with and without underlying mitral valve disease. Heart. 2004 Apr;90(4):400-5.
19: Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H,
Gummert JF, Dhein S. Expression of angiotensin II receptors in human left and
right atrial tissue in atrial fibrillation with and without underlying mitral
valve disease. J Am Coll Cardiol. 2003 Nov 19;42(10):1785-92.